This post was originally published on this site
“We don’t want to create a soup-to-nuts portfolio of all sorts of consumer health care assets. What we want to do is consistently grow and develop around nutrition and metabolism as our angle into consumer health,” Mark Schneider said during a call on the group’s full-year results.
“A broad-based consumer health care portfolio is something that we kind of signalled low interest in from the beginning, and we stay true to that. And I think it is truly paying off.”
GlaxoSmithKline (NYSE:GSK) last month rejected a 50-billion-pound offer from Nestle rival Unilever (NYSE:UL) for its consumer goods arm, saying it would stick to its plan of spinning off the unit.
